AKBA - Akebia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.4200
-0.0100 (-0.23%)
As of 12:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.4300
Open4.4500
Bid4.4300 x 800
Ask4.4400 x 1200
Day's Range4.4200 - 4.6500
52 Week Range4.0900 - 10.8650
Volume374,825
Avg. Volume1,151,585
Market Cap520.954M
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-2.5630
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.48
Trade prices are not sourced from all markets
  • When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
    Simply Wall St.6 days ago

    When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

    Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...

  • Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)
    Insider Monkey6 days ago

    Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)

    Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT

    Q1 2019 Akebia Therapeutics Inc Earnings Call

  • Business Wire15 days ago

    Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease

    AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy

  • Business Wire22 days ago

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebia’s common stock on May 31, 2019, including an option to purchase 250,000 shares granted to Dell Faulkingham, Akebia’s newly-hired Senior Vice President, Chief Commercial Officer. The options were granted as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $4.45 per share, which is equal to the closing price of Akebia’s common stock on the grant date.

  • Business Wire28 days ago

    Akebia Therapeutics to Participate in Upcoming Investor Conferences

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

  • Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript

    AKBA earnings call for the period ending March 31, 2019.

  • Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)

    The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]

  • Associated Press2 months ago

    Akebia Therapeutics: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for one-time gains and costs, were 44 cents per share. The results fell short of Wall Street expectations. ...

  • Business Wire2 months ago

    Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

    CAMBRIDGE, Mass.-- -- Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3 INNO 2 VATE Studies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney ...

  • Seth Klarman Keeps Buying This Biotech Stock
    GuruFocus.com2 months ago

    Seth Klarman Keeps Buying This Biotech Stock

    Akebia Therapeutics (AKBA) was a top stock pick by Seth Klarman (Trades, Portfolio) last quarter. Warning! GuruFocus has detected 4 Warning Signs with AKBA. Last June, Akebia agreed to combine with Keryx Biopharmaceuticals (KERX), of which Klarman was a major shareholder, controlling more than 20% of the fully diluted stock.

  • Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know

    Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, and its strategic development collaborator Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC), announced today that four posters highlighting the unmet clinical need and economic burden among patients with anemia due to chronic kidney disease will be presented at the 2019 Spring Clinical Meetings of the National Kidney Foundation (NKF), to be held May 8 through May 12, 2019 at the Hynes Convention Center in Boston, MA.

  • Business Wire2 months ago

    Akebia Therapeutics to Report First Quarter 2019 Financial Results

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, May 9, 2019 to discuss its first quarter financial results. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 4271217.

  • Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
    Zacks3 months ago

    Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

    Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.

  • Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
    Business Wire3 months ago

    Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement

    The Vifor Pharma Group (SIX:VIFN) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.

  • Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
    Business Wire3 months ago

    Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement

    The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.

  • Business Wire3 months ago

    Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York. A live webcast of the presentation will be available on the company’s website at www.akebia.com. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.

  • CNW Group3 months ago

    Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

    PETACH TIKVA, Israel , April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (GUD.TO) ("Knight" or the "Company"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the "Nominees") for election to Knight's Board of Directors (the "Board") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison.

  • GlobeNewswire3 months ago

    Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications

    NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GuruFocus.com3 months ago

    Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Akebia Therapeutics Inc is a biopharmaceutical company. Akebia Therapeutics Inc had annual average EBITDA growth of 19.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with AKBA.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Akebia Therapeutics Inc Earnings Call